Killer Cell Immunoglobulin-like Receptors and Their HLA Ligands are Related with the Immunopathology of Chagas Disease

PLoS Neglected Tropical Diseases

Volumn 9, Issue 5, 2015, Pages

  Ayo, Christiane Maria ^a   Reis, Pâmela Guimarães ^a   Dalalio, Márcia Machado de Oliveira ^a   Visentainer, Jeane Eliete Laguila ^a   Oliveira, Camila de Freitas ^a   de Araújo, Silvana Marques ^a   de Oliveira Marques, Divina Seila ^b   Sell, Ana Maria ^a  

^a STATE UNIVERSITY OF MARINGÁ   (Brazil)

^b STATE UNIVERSITY OF LONDRINA   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

CD45 ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR; HLA A ANTIGEN; HLA B ANTIGEN; HLA C ANTIGEN; KILLER CELL IMMUNOGLOBULIN LIKE RECEPTOR 2DL2; KIR2DL2 PROTEIN, HUMAN; KIR2DS2 PROTEIN, HUMAN; LIGAND;

ADULT; ARTICLE; CASE CONTROL STUDY; CHAGAS DISEASE; CONTROLLED STUDY; ELECTROCARDIOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GENE FREQUENCY; GENOTYPE; GENOTYPING TECHNIQUE; HEART DISEASE; HUMAN; IMMUNOFLUORESCENCE TEST; IMMUNOPATHOLOGY; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; SEROLOGY; TRYPANOSOMA CRUZI; BRAZIL; CHAGAS CARDIOMYOPATHY; GENETICS; IMMUNOLOGY; MIDDLE AGED; PARASITOLOGY; PATHOGENICITY; PATHOLOGY; RISK FACTOR;

ADULT; BRAZIL; CASE-CONTROL STUDIES; CHAGAS CARDIOMYOPATHY; CHAGAS DISEASE; FEMALE; GENOTYPE; HLA-A ANTIGENS; HLA-B ANTIGENS; HLA-C ANTIGENS; HUMANS; LIGANDS; MALE; MIDDLE AGED; RECEPTORS, KIR; RECEPTORS, KIR2DL2; RISK FACTORS; TRYPANOSOMA CRUZI;

EID: 84930676288     PISSN: 19352727     EISSN: 19352735     Source Type: Journal    
DOI: 10.1371/journal.pntd.0003753     Document Type: Article

References (55)

1. WHO. Chagas disease (American trypanosomiasis)—Fact sheet 340.
2. Andrade LO, Machado CRS, Chiari E, Pena SDJ, Macedo AM, Differential tissue distribution of diverse clones of Trypanosoma cruzi in infected mice. Mol Biochem Parasitol. 1999;100: 163–172. 10391378
3. Marin-Neto JA, Cunha-Neto E, Maciel BC, Simoes MV, Pathogenesis of chronic Chagas heart disease. Circulation. 2007;115: 1109–1123. 17339569
4. Arce-Fonseca M, Ballinas-Verdugo MA, Reyes PA, Aranda-Fraustro A, Monteon VM, Autoantibodies to human heart conduction system in Chagas’ disease. Vector Borne Zoonotic Dis. 2005;5: 233–236. 16187891
5. Manoel-Caetano FS, Silva AE, Implications of genetic variability of Trypanosoma cruzi for the pathogenesis of Chagas disease. Cad Saude Publica. 2007;23: 2263–2274. 17891288
6. Souza PE, Rocha MO, Rocha-Vieira E, Menezes CA, Chaves AC, Gollob KJ, et al. Monocytes from patients with indeterminate and cardiac forms of Chagas disease display distinct phenotypic and functional characteristics associated with morbidity. Infect Immun. 2004;72: 5283–5291. 15322024
7. Cunha-Neto E, Nogueira LG, Teixeira PC, Ramasawmy R, Drigo SA, Goldberg AC, et al. Immunological and non-immunological effects of cytokines and chemokines in the pathogenesis of chronic Chagas disease cardiomyopathy. Mem Inst Oswaldo Cruz. 2009;104: 252–258. 19753481
8. Biolo A, Ribeiro AL, Clausell N, Chagas cardiomyopathy—where do we stand after a hundred years? Prog Cardiovasc Dis. 2010;52: 300–316. doi: 10.1016/j.pcad.2009.11.008 20109600
9. Reis DD, Jones EM, Tostes S, Lopes ER, Gazzinelli G, Colley DG, et al. Characterization of inflammatory infiltrates in chronic chagasic myocardial lesions: presence of tumour necrosis factor-alpha+ cells and dominance of granzyme A+, CD8+ lymphocytes. Am J Trop Med Hyg. 1993;48: 637–644. 8517482
10. Higuchi MD, Ries MM, Aiello VD, Benvenuti LA, Gutierrez PS, Bellotti G, et al. Association of an increase in CD8+ T cells with the presence of Trypanosoma cruzi antigens in chronic, human, chagasic myocarditis. Am J Trop Med Hyg. 1997;56: 485–489. 9180594
11. Vitelli-Avelar DM, Sathler-Avelar R, Dias JCP, Pascoal VP, Teixeira-Carvalho A, Lage OS, et al. Chagasic patients with indeterminate clinical form of the disease have high frequencies of circulating CD3+CD16–CD56+ natural killer T cells and CD4+CD25 high regulatory T lymphocytes. Scand J Immunol. 2005;62: 297–308. 16179017
12. Vitelli-Avelar DM, Sathler-Avelar R, Massara RL, Borges JD, Lage OS, Lana M, et al. Are increased frequency of macrophage-like and natural killer (NK) cells, together with high levels of NKT and CD4+CD25high T cells balancing activated CD8+ T cells, the key to control Chagas’ disease morbidity? Clin Exp Immunol. 2006;145: 81–92. 16792677
13. Sathler-Avelar R, Vitelli-Avelar DM, Teixeira-Carvalho A, Martins-Filho AO Innate immunity and regulatory T-cells in human Chagas disease: what must be understood? Mem Inst Oswaldo Cruz. 2009;104: 246–251. 19753480
14. Ljunggren HG, Kärre K, In search of the “missing self”: MHC molecules and NK cell recognition. Immunol Today. 1990;11: 237–244. 2201309
15. Middleton D, Gonzelez F, The extensive polymorphism of KIR genes. Immunology. 2010;129: 8–19. doi: 10.1111/j.1365-2567.2009.03208.x 20028428
16. Green S, Pichyangkul S, Vaughn DW, Kalayanarooj S, Nimmannitya S, Nisalak A, et al. Early CD69 expression on peripheral blood lymphocytes from children with dengue haemorrhagic fever. J Infect Dis. 1999;180: 1429–1435. 10515800
17. Martin MP, Gao X, Lee JH, Nelson GW, Detels R, Goedert J, et al. Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat Gen. 2002;31: 429–434.
18. Alter G, Martin MP, Teigen N, Carr WH, Suscovich TJ, Schneidewind A, et al. Differential natural killer cell-mediated inhibition of HIV-1 replication based on distinct KIR/HLA subtypes. J Exp Med. 2007;204: 3027–3036. 18025129
19. Montes-Cano MA, Caro-Oleas JL, Romero-Gómez M, Diago M, Andrade R, Carmona I, et al. HLA-C and KIR genes in hepatitis C virus infection. Hum Immunol. 2005;66:1106–1109. 16571411
20. Marangon AV, Silva GF, de Moraes CF, Grotto RM, Pardini MI, de Pauli DS, et al. KIR genes and their human leukocyte antigen ligands in the progression to cirrhosis in patients with chronic hepatitis C. Hum Immunol. 2011;72: 1074–1078. doi: 10.1016/j.humimm.2011.08.017 21920398
21. Méndez A, Granda H, Meenagh A, Contreras S, Zavaleta R, Mendoza MF, et al. Study of KIR genes in tuberculosis patients. Tissue Antigens. 2006;68: 386–389. 17092251
22. Lu C, Shen YJ, Deng YF, Wang CY, Fan G, Liu YQ, et al. Association of killer cell immunoglobulin-like receptors with pulmonary tuberculosis in Chinese Han. Genet Mol Res. 2012;11: 1370–1378. doi: 10.4238/2012.May.15.7 22653583
23. Franceschi DS, Mazini OS, Rudnick CC, Sell AM, Tsuneto LT, de Melo FC, et al. Association between killer-cell immunoglobulin-like receptor (KIR) genotypes and leprosy in Brazil. Tissue Antigens. 2008;72: 478–482. doi: 10.1111/j.1399-0039.2008.01127.x 18778326
24. Jarduli LR, Alves HV, de Souza-Santana FC, Marcos EV, Pereira AC, Dias-Baptista IM, et al. Influence of KIR genes and their HLA ligands in the pathogenesis of leprosy in a hyperendemic population of Rondonópolis, Southern Brazil. BMC Infect Dis. 2014;14: 438. doi: 10.1186/1471-2334-14-438 25117794
25. Taniguchi M, Kawabata M, KIR3DL1/S1 genotypes and KIR2DS4 allelic variants in the AB KIR genotypes are associated with Plasmodium-positive individuals in malaria infection. Immunogenetics. 2009;61: 717–730. doi: 10.1007/s00251-009-0401-z 19859704
26. Yindom LM, Forbes R, Aka P, Jonha O, Jeffries D, Jallow M, et al. Killer-cell immunoglobulin-like receptors and malaria caused by Plasmodium falciparum in The Gambia. Tissue Antigens. 2012;79: 104–113. doi: 10.1111/j.1399-0039.2011.01818.x 22220719
27. Hirayasu K, Ohashi J, Kashiwase K, Hananantachai H, Naka I, Ogawa A, et al. Significant association of KIR2DL3-HLA-C1 combination with cerebral malaria and implications for co-evolution of KIR and HLA. PLoS Pathog. 2012;8: e1002565. doi: 10.1371/journal.ppat.1002565 22412373
28. Augusto DG, Lobo-Alves SC, Melo MF, Pereira NF, Petzl-Erler ML, Activating KIR and HLA Bw4 ligands are associated to decreased susceptibility to Pemphigus Foliaceus, an autoimmune blistering skin disease. PLoS One. 2012; 7: e39991. doi: 10.1371/journal.pone.0039991 22768326
29. Luszczek W, Mánczak M, Cislo M, Nockowski P, Wiśniewski A, Jasek M, et al. Gene for the activating natural killer cell receptor, KIR2DS1, is associated with susceptibility to psoriasis vulgaris. Hum Immunol. 2004; 65: 758–766. 15310528
30. Momot T, Koch S, Hunzelmann N, Krieng T, Ulbricht K, Schmidt RE, et al. Association of killer cell immunoglobulin-like receptors with scleroderma. Arthritis Rheum. 2004;50: 1561–1565. 15146426
31. Yen JH, Moore BE, Nakajima T, Scholl D, Schaid DJ, Weyand CM, et al. Major histocompatiblity complex class I recognizing receptors are disease risk genes in rheumatoid arthritis. J Exp Med. 2001;193: 1159–1167. 11369787
32. Hollenbach JA, Ladner MB, Saeteurn K, Taylor KD, Mei L, Haritunians T, et al. Susceptibility to Crohn's disease is mediated by KIR2DL2/KIR2DL3 heterozygosity and the HLA-C ligand. Immunogenetics. 2009;61: 663–671. doi: 10.1007/s00251-009-0396-5 19789864
33. Carrington M, Wang S, Martin MP, Gao X, Schiffman M, Cheng J, et al. Hierarchy of resistance to cervical neoplasia mediated by combinations of killer immunoglobulin-like receptor and human leukocyte antigen loci. J Exp Med. 2005;201: 1069–1075. 15809352
34. Ashouri E, Dabbaghmanesh MH, Rowhanirad S, Bakhshayeshkaram M, Ranjbar Omrani G, Activating KIR2DS5 receptor is a risk for thyroid cancer. Hum Immunol. 2012;73: 1017–1022. doi: 10.1016/j.humimm.2012.07.325 22836040
35. Wiśniewski A, Jankowska R, Passowicz-Muszyńska E, Majorczyk E, Nowak I, Frydecka I, et al. KIR2DL2/S2 and HLA-C C1C1 genotype is associated with better response to treatment and prolonged survival of patients with non-small cell lung cancer in a Polish Caucasian population. Hum Immunol. 2012;73: 927–931. doi: 10.1016/j.humimm.2012.07.323 22836042
36. De Re V, Caggiari L, De Zorzi M, Talamini R, Racanelli V, D' Andrea M, et al. Genetic Diversity of the KIR/HLA System and Outcome of Patients with Metastatic Colorectal Cancer Treated with Chemotherapy. PLoS One. 2014;9: e84940. doi: 10.1371/journal.pone.0084940 24497922
37. Franceschi DS, de Souza CA, Aranha FJ, Cardozo DM, Sell AM, Visentainer JEL, Importance of immunoglobulin-like receptors in allogeneic hematopoietic stem cell transplantation. Rev Bras Hematol Homoter. 2011;33: 126–130. doi: 10.5581/1516-8484.20110033 23284260
38. Probst CM, Bompeixe EP, Pereira NF, de O Dalalio MM, Visentainer JE, Tsuneto LT, et al. HLA polymorphism and evaluation of European, African, and Amerindian contribution to the white and mulatto populations from Paraná, Brazil. Hum Biol. 2000;72: 597–617. 11048789
39. Cardozo DM, Guelsin GA, Clementino SL, Melo FC, Souza CD, Braga MA, et al. DNA extraction from coagulated human blood for application in genotyping techniques for human leukocyte antigen and immunoglobulin-like receptors. Rev Soc Bras Med Trop. 2009;42: 651–656. 20209349
40. Kulkarni S, Martin MP, Carrington M, The Yin and Yang of HLA and KIR in human disease. Semin Immunol. 2008; 20: 343–352. doi: 10.1016/j.smim.2008.06.003 18635379
41. Thananchai H, Gillespie G, Martin MP, Bashirova A, Yawata N, Yawata M, et al. Allele-specific and peptide-dependent interactions between KIR3DL1 and HLA-A and HLA-B. J Immunol. 2007;178: 33–37. 17182537
42. Rudnick CC, Franceschi DS, Marangon AV, Guelsin GA, Sell AM, Visentainer JEL, Killer cell immunoglobulin-like receptor gene diversity in a Southern Brazilian population from the state of Paraná. Hum Immunol. 2008;69: 872–876. doi: 10.1016/j.humimm.2008.09.002 18848853
43. Khakoo SI, Carrington M, KIR and disease: a model system or system of models? Immunol Rev. 2006; 214: 186–201. 17100885
44. Moesta AK, Parham P, Diverse functionality among human NK cell receptors for the C1 epitope of HLA-C: KIR2DS2, KIR2DL2, and KIR2DL3. Front Immunol. 2012;22: 336.
45. Khakoo SI, Thio CL, Martin MP, Brooks CR, Gao X, Astemborski J, et al. HLA and NK cell inhibitory receptor genes in resolving hepatitis C virus infection. Science. 2004;305: 872–874. 15297676
46. Williams AP, Bateman AR, Khakoo SI, Hanging in balance. KIR and their role in disease. Mol Interv. 2005;5: 226–240. 16123537
47. Nelson GW, Martin MP, Gladman D, Wade J, Trosdale J, Carrington M, Cutting edge heterozygote advantage in autoimmune disease: hierarchy of protection/susceptibility conferred by HLA and killer Ig-like receptor combinations in psoriatic arthritis. J Immunol. 2004; 173: 4273–4276. 15383555
48. Bashirova AA, Martin MP, McVicar DW, Carrington M, The killer immunoglobulin-like receptor gene cluster: tuning the genome for defence. Annu Rev Genomics Hum Genet. 2006;7: 277–300. 16824023
49. David G, Djaoud Z, Willem C, Legrand N, Rettman P, Gagne K, et al. Large spectrum of HLA-C recognition by killer Ig-like receptor (KIR) 2DL2 and KIR2DL3 and restricted C1 specificity of KIR2DS2: dominant impact of KIR2DL2/KIR2DS2 on KIR2D NK cell repertoire formation. J Immunol. 2013;191: 4778–4788. doi: 10.4049/jimmunol.1301580 24078689
50. Middleton D, Diler AS, Meenagh A, Sleator C, Gourrad PA, Killer immunoglobulin-like receptors (KIR2DL2 and/or KIR2DS2) in presence of their ligand (HLA-C1 group) protect against chronic myeloid leukaemia. Tissue Antigens. 2009;73: 553–560. doi: 10.1111/j.1399-0039.2009.01235.x 19493232
51. Salim PH, Jobim M, Bredemeier M, Chies JA, Schlottfeld J, Killer cell immunoglobulin-like receptor (KIR) genes in systemic sclerosis. Clin Exp Immunol. 2010;160: 325–330. doi: 10.1111/j.1365-2249.2010.04095.x 20082621
52. Al Omar S, Middleton D, Marshall E, Porter D, Xinarianos G, Raji O, et al. Associations between genes for killer immunoglobulin-like receptors and their ligands in patients with solid tumors. Hum Immunol. 2010;71: 976–981. doi: 10.1016/j.humimm.2010.06.019 20600442
53. Lowe DP, Cook MA, Bowman SJ, Briggs DC, UK Sjogren’s Interest Group. Association of killer cell immunoglobulin-like receptors with primary Sjogren’s syndrome. Rheumatology. 2009;48: 359–362. doi: 10.1093/rheumatology/ken503 19181658
54. Cunha-Neto E, Teixeira PC, Nogueira LG, Mady C, Lanni B, Stolf N, et al. New concepts on the pathogenesis of chronic Chagas cardiomyopathy: myocardial gene and protein expression profiles. Rev Soc Bras Med Trop. 2006;39: 59–62. 17605209
55. Cooke A, Zaccone P, Raine T, Phillips JM, Dunne DW, Infection and autoimmunity: are we winning the war, only to lose the peace? Trends Parasitol. 2004;20: 316–321. 15193562